Cipla wins FDA OK for generic Imitrex
Imitrex Nasal Spray and its generic equivalents had a market value of approximately $53.3 million for the 12 months ended December 2020, according to IQVIA.
Adult patients with migraines will soon have a new generic treatment.
The Food and Drug Administration has given thumbs up to Cipla’s sumatriptan nasal spray, in a dosage strength of 20 mg.
The product is the generic of GlaxoSmithKline’s Imitrex Nasal Spray.
It is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults.
Imitrex Nasal Spray and its generic equivalents had a market value of approximately $53.3 million for the 12 months ended December 2020, according to IQVIA.